Company intelligence / Profile preview

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

Shenzhen, Guangdong, Chinacrpharm.com ↗

Ownership: Public · 000999
Employees: ~20318
Development stage: Commercial

Overview

The company is a major player in the Chinese pharmaceutical industry, focusing on a wide range of therapeutic areas. It reported a net income of 1.27 billion yuan in the first quarter of 2025.

Therapeutic areas: OncologyOtherDermatologyRheumatologyGastroenterologyCardiovascularInfectious Diseases
Modalities: Small moleculesTraditional Chinese Medicine (TCM)Formula Granules
Industry: Biotech

Drug pipeline

23 assets

Qizhi Weitong granules

22 more assets in the full pipeline.

Request access →

Partnerships

Recent plans include acquiring a stake in Tasly Pharma Group.

Beyond the preview

Go deeper on China Resources Sanjiu Medical & Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Resources Sanjiu Medical & Pharmaceutical Co., Ltd..

Explore the full profile